Connor, Clark & Lunn Investment Management (CC&L)’s Unity Biotechnology UBX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-16,204	Closed	-$64K	–	1437
2022 Q3	$64K	Buy	+16,204	New	+$102K	﹤0.01%	1056
2022 Q2	–	Sell	-3,392	Closed	-$38K	–	1208
2022 Q1	$38K	Sell	3,392 -6,036	-64%	-$67.7K	﹤0.01%	1006
2021 Q4	$138K	Buy	+9,428	New	+$206K	﹤0.01%	1009

Other funds holding UBX

AWA

Arete Wealth Advisors Chicago, Illinois $3.05B AUM 42.78% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s UBX Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Unity Biotechnology (UBX) in Q4 2022, closing a stake of 16,204 shares — an estimated $64K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in UBX in Q4 2021 and held it in 3 quarters. The position peaked at $138K in Q4 2021. 54 funds tracked by Wall St. Rank hold UBX as of Q4 2022.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Unity Biotechnology position as of Q4 2022 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 16,204 Unity Biotechnology shares in Q4 2022, an estimated $64K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Unity Biotechnology in Q4 2021 and held it in 3 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Unity Biotechnology position peaked at $138K in Q4 2021.
54 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.